- Acyclovir transdermal delivery system
-
A transdermal formulation for providing antiviral effect in dermis or epidermis, wherein comprising (a) 0.01 to 30 weight percent of antiviral drug; (b) 0.05 to 20 weight percent of a Chinese medicine enhancer; and (c) a pharmaceutical acceptable vehicles. The antiviral drug is selected from the group consisting of ACV(Acyclovir), Carbovir, DDA(2',3'-Dideoxyadnosine), HPMPA(1-(3-Hydroxy-2-phosphonylmethoxylpropyl)-adenosine), DHPG(Ganciclovir), Desciclovir, IDC (5-Iodo-2'-deoxy-cytidine), Vidarabine(Ara-A), DDI(2',3'-Dideoxyinosine), Cordycepin, Cytarabine, Deoxyguanosine, d4T(2',3'-Didehydro-3'-deoxythymidine), FIAC(2'-Fluoro-5-iodoaracytosine), AZT(ZDV, Zidovudine), Ara-T(1- beta -D-Ara-binofuranosylthymine), Deoxythymidine, Ribavirin, EDU(5-Ethyl-2'-deoxy-uridine), Enviroxime, Amantadine, Arildone, HPMPC(9-(3-Hydroxy-2-phosphonyl-methoxyl-propyl)cytidine), Riboxamide, Rimantidine, Tromantadine, Foscamet sodium, Moroxydine, F3T(5-Trifluoro-methyl-2'-deoxy-uridine), BVDU (Bromovinyldeoxyuridine). Preferably, the Chinese medicine enhancer is oleanolic acid, and the pharmaceutical acceptable vehicles is polyethylene glycols.
- -
-
-